


## RP101988

<b>Cat. No.:</b>	HY-136578		
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>22</sub> N <sub>4</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	418.45		
<b>Target:</b>	LPL Receptor; Drug Metabolite		
<b>Pathway:</b>	GPCR/G Protein; Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (298.72 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.3898 mL	11.9489 mL	23.8977 mL
	5 mM	0.4780 mL	2.3898 mL	4.7795 mL
	10 mM	0.2390 mL	1.1949 mL	2.3898 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC<sub>50</sub>s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectively<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

S1PR1	S1PR5
0.19 nM (EC50)	32.8 nM (EC50)

#### In Vitro

RP101988 is a substrate of P-gp and breast cancer resistance protein (BCRP) drug transporters<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Tran JQ, et al. Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study. Clin Pharmacol Drug Dev. 2018;7(3):263-276.

[2]. Gilardi D, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD [published

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA